Breaking News:
Voiant Acquires Voxeleron

VOIANT, a leader in clinical trial imaging solutions, is thrilled to announce the acquisition of Voxeleron, a pioneering company in AI-driven ophthalmic image analysis. This strategic acquisition marks a significant advancement in Voiant’s mission to accelerate the development of innovative treatments for eye diseases.

Read about it here

Accelerating Insights with Cutting-Edge Clinical Trial Solutions

Led by industry-leading experts and powered by advanced technology, we deliver operational excellence and flawless execution—ensuring the fastest path to high-quality clinical imaging endpoint data.

Highest Quality Endpoints

Driven by a common purpose to deliver the highest quality data to support your clinical development goals.

Faster Turn-Around-Time

Industry’s only purpose-built AI platform to accelerate imaging processing and analysis.

Scientific Accuracy

Renowned scientists, bringing differentiative expertise and experience to your clinical programs.

Learn about our solutions

Therapeutic Areas

Oncology

With over 30 years of experience and multiple drug approvals, Voiant is the partner of choice for Oncology clinical trials from early to late phases. Leveraging our subspecialty trained clinical readers with experience in utilizing any oncology assessment criteria and a purposed built AI-driven platform to support efficient image processing and analysis, Voiant is able to deliver high-quality imaging endpoints in record time.

Learn More

Ophthalmology

Voiant has been the leading Independent Reading Center for ophthalmic imaging for over three decades. Our experienced staff of in-house, full-time certified readers with years of experience providing reliable and reproducible data, along with our extensive network of over 2,700 registered sites, and our history of successful interactions with multiple regulatory authorities, makes Voiant the obvious choice for your Ophthalmic programs and Ocular Safety studies.

Learn more

Respiratory

With experience in advanced biomarkers such as COPD measures, including volumetrics, density, and airway analytics, we’re equipped to provide respiratory trials with actionable data for decision-making and successful regulatory submissions.

Learn more

Clinical Data Evolved

Industry’s top people with experience, expertise and the ability to execute

AI plus the human element, all from one partner. A premier network of experts, each with years of imaging endpoint data experience, taking charge and producing results. Our offices across the globe are staffed with real people, there when you need them, delivering the highest levels of client care.

Schedule an exploratory discussion

By The Numbers

With experience in Phase I-IV global trials spanning across multiple therapeutic areas and resulting in many therapy approvals, Voiant is the imaging CRO partner to tackle clinical trial imaging hurdles and bring promising therapies to the people who need them.

0 +

Years of Experience

Successful Trials

0 +

Billion Images Processed

Countries Supported

Clients Served

Drug Approvals & Counting

Results that speak for themselves

Huma Qamar MD, MPH, CMI

“A huge thank-you to Voiant, our trusted reading center, for their precision, reliability, and speed in supporting our gene therapy trials. They have played a critical role in advancing our mission to bring transformative treatments to patients with retinal diseases. Their integration of Voxeleron’s AI-powered imaging is raising the bar — delivering faster analysis, deeper insights, and outstanding quality for every study.”

Meredith Mundy

“The team’s experience working at clinical research sites comes through in the responsiveness to any and all inquiries from us as the sponsor and the clinical sites directly, and aligning under Voiant has expanded their global footprint and ability to augment global trial needs.”

Kristen Gullo

“I am grateful for the outstanding services provided by Voiant. The Voiant team provided invaluable expertise in guiding the design and operational considerations of a blinded independent central review of imaging for our unique pediatric oncology registration program. Their proficiency in this specialized area significantly enhanced the reliability and accuracy of our research data. As a result of the high standards of their process and strong execution, the outcomes of the BICR were unequivocally successful and provided vital support for FDA agreement with the contents of our planned efficacy package for review. Voiant’s contributions certainly elevated the quality of our research to bring us a step closer to our product registration goal, and we highly recommend their services to anyone seeking a qualified and reliable and imaging services vendor. We look forward to a future opportunity to collaborate with Voiant.”

Let’s talk

Discover how our AI-powered imaging platform helps biopharma teams bring groundbreaking therapies to market faster and ultimately improve patient outcomes.

Request a demo

Breaking News:Voiant Acquires Voxeleron